NCT07428798Completed
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration
Effects of Subtenon Autologous Platelet-Rich Plasma Injection on Geographic Atrophy Progression, Visual Function, and Quality of Life in Advanced Dry Age-Related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD). PRP is derived from the patient's own blood and contains growth factors that may support cell survival and tissue repair. These factors are thought to help reduce retinal cell loss and slow disease progression. Three PRP injections were administered to the better-seeing eye at 4-week intervals, while the fellow eye served as an untreated control. Participants were followed from baseline to 10 weeks (two weeks after the third injection). The aim is to compare changes in RPE atrophy area, photoreceptor loss, and visual function between treated and untreated eyes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 9 Feb 2026
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Oct 2024
- Lead sponsor
- Marmara University Pendik Training and Research Hospital
- Diseases
- Macular degeneration
- NCT number
- NCT07428798
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 1 Jul 2024 to the primary completion date, 30 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous intraocular surgery other than cataract surgery
Other illness
- Any ocular disease other than dry AMD that could affect retinal structure or function
- Systemic or ocular conditions that could affect study compliance or visual testing reliability
Other
- Media opacities interfering with retinal imaging assessment
- Evidence of macular neovascularization
Who the study is looking for
- Age ≥ 60 years
- Diagnosis of advanced dry age-related macular degeneration (AMD) in both eyes
- No previous ocular treatment for AMD
- History of ocular surgery limited to cataract surgery performed ≥1 year prior
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Marmara University School of Medicine, Department of Ophthalmology Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.